Anavex Life Sciences has announced encouraging preliminary results from
their ANAVEX®2-73 (blarcamesine) Phase 2 extension study, targeting Parkinson’s
disease dementia. This 48-week open-label study demonstrated notable
improvements in patients’ symptoms, reinforcing the potential efficacy of
ANAVEX®2-73.

Parkinson’s disease is a chronic and progressive neurodegenerative disorder affecting millions
worldwide. Current treatments focus primarily on symptom management, often
becoming less effective as the disease progresses. Anavex Life Sciences aims to
address this gap by developing ANAVEX®2-73, an oral small molecule that
activates the sigma-1 receptor (SIGMAR1), a crucial component in restoring
neural cell homeostasis. 

The study involved patients continuing their regular Parkinson’s medication regimen while
receiving ANAVEX®2-73. Results revealed significant improvements across all
efficacy endpoints, including the Movement Disorder Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) and the Clinical Global Impression –
Improvement (CGI-I). These findings could mark a substantial advancement in
Parkinson’s disease treatment. 

Dr. Christopher U Missling, President & CEO of Anavex, highlighted the importance of these results. “The consistent
improvement in patients’ clinical symptoms under ANAVEX®2-73 treatment suggests
its potential to not only slow but potentially reverse the debilitating
symptoms of Parkinson’s disease,” he stated. 

The study also faced unique challenges, including delays due to the COVID-19 pandemic,
resulting in a ‘drug holiday’. This unintended pause allowed researchers to
observe the trajectory of clinical scores without ANAVEX®2-73, further
validating its efficacy upon resumption. 

Anavex Life Sciences plans to advance to a pivotal 6-month trial, bolstered by these
promising findings. The Michael J. Fox Foundation has already awarded Anavex a
research grant for an imaging-focused clinical trial, underscoring the
therapeutic promise of ANAVEX®2-73. 

As Anavex continues to explore the full potential of ANAVEX®2-73, the medical community remains
cautiously optimistic about the future implications for Parkinson’s disease
treatment. Refer to this article, for related information. 

Learn more about Anavex on https://www.biospace.com/article/releases/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-business-update/